NervGen restates Q2 results to CAD 10.8 million net income from net loss
NGEN•NervGen Pharma corrected its financial statements, reporting net income of CAD 8.88 million for the six months ended June 30, 2026, instead of a net loss of CAD 30.89 million. The corrections reduced warrant derivative liabilities and increased shareholders’ equity, without affecting cash flows or cash runway.
1. Restated financial statements
NervGen Pharma restated financial statements to correct material stock-option and warrant-derivative valuation errors, as well as misclassified share issuance costs. For the six months ended June 30, 2026, net income was corrected to CAD 8.88 million from a net loss of CAD 30.89 million.
2. Liabilities and equity
Warrant derivative liabilities at June 30, 2026, fell to CAD 39.06 million from CAD 68.63 million, while shareholders’ equity rose to CAD 46.84 million from CAD 17.28 million. The errors affected periods from fiscal 2020 through June 30, 2026; the corrections did not affect cash flows or cash runway.
